Iterum Therapeutics PLC - Asset Resilience Ratio
Iterum Therapeutics PLC (ITRM) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Iterum Therapeutics PLC's Asset Resilience Ratio has changed over time. Check Iterum Therapeutics PLC strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Iterum Therapeutics PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ITRM market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Iterum Therapeutics PLC maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Iterum Therapeutics PLC Industry Peers by Asset Resilience Ratio
Compare Iterum Therapeutics PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Iterum Therapeutics PLC (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Iterum Therapeutics PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $44.59 Million | -- |
| 2023-12-31 | 68.01% | $17.86 Million | $26.26 Million | +8.59pp |
| 2022-12-31 | 59.42% | $39.71 Million | $66.83 Million | +0.52pp |
| 2021-12-31 | 58.90% | $53.90 Million | $91.51 Million | +51.70pp |
| 2020-12-31 | 7.20% | $2.36 Million | $32.79 Million | +7.19pp |
| 2019-12-31 | 0.00% | $1.14K | $25.75 Million | -40.87pp |
| 2018-12-31 | 40.87% | $40.00 Million | $97.87 Million | -24.85pp |
| 2017-12-31 | 65.72% | $30.73 Million | $46.76 Million | +64.22pp |
| 2016-12-31 | 1.50% | $404.00K | $26.92 Million | -- |
About Iterum Therapeutics PLC
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with lim… Read more